In this article
IADR Report: Nicotine and Carcinogen Exposure
At the 96th Congress of the International Association for Dental Research (IADR), Benjamin Chaffee of the University of California, San Francisco published a report on nicotine and carcinogens in tobacco.
Tobacco use is still the main cause of oral cancer, but with the increase in the use of non-cigarette tobacco products and the dual use of multiple product types, the tobacco growing industry has been developing. The study reported on the assessment of exposure to known carcinogens of different types of tobacco products used alone or in combination.
Study Methodology and Product Classification
The data comes from the tobacco and healthy population assessment, which includes a sample of American adults who provide urine samples for analysis of tobacco-specific nitrosamines (TSNAs) N’-nitroso-nornicotinine (NNN), which is A known carcinogen of the mouth and esophagus.
Classified according to the way of tobacco use, including cigarettes, cigars, hookahs, pipe tobacco, blunt (cigars containing hemp) and smokeless, such as including wet snuff, chewing tobacco and snuff are electronic cigarettes and nicotine replacement products. For each product, the most recent use refers to the previous 3 days, and the non-use refers to no smoking within 30 days.
Comparative Analysis of Carcinogen Levels
All tobacco use categories show increased nicotine and TSNA concentrations relative to non-users. TSNA has the highest exposure to smokeless tobacco users, whether used alone or with other types of products. Although nicotine exposure is comparable, the levels of NNN and NNAL using only e-cigarettes are lower than other tobacco categories. However, the simultaneous use of combustible tobacco by most e-cigarette users resulted in TSNA exposure similar to that of exclusive smokers.
Analysis shows that the majority of non-cigarette tobacco users are exposed to carcinogens that are at or above the exposure levels of exclusive cigarette smokers, and may still face significant risks.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.
